Christopher J. Betti

Background

About Christopher J. Betti

A patent attorney with over 20 years of experience, Chris concentrates his practice on biotechnology and pharmaceutical patent matters with an emphasis on pre-litigation counseling often involving the strategic implementation of patent prosecution tactics, and product life-cycle management. Currently he is the global lead of Morgan Lewis’ biologics and biosimilars efforts and has been involved in developing patent prosecution strategies for innovators and providing strategic risk assessments for biosimilar applicants with regard to over 35 biologics. Chris has also been the technical architect behind many high-profile bio/pharmaceutical patent litigations including those involving antibody, antisense, and vaccine technology. Christopher also devotes a significant portion of his practice to intellectual property portfolio management, patent preparation and prosecution, patent litigation, due diligence analysis associated with venture capital financing and public offerings, and opinions and strategic advice relating to complex patentability, patent validity, infringement, and freedom-to-operate issues. Additionally, Christopher regularly counsels innovators and biosimilar applicants in all matters related to the Biologics Price Competition and Innovation Act. He provides US Food and Drug Administration regulatory advice relating to biologics and pharmaceuticals, including advice concerning Orange Book patent listings and patent term extensions. Christopher represents technology companies in trials before US district courts and in Section 337 investigations in the US International Trade Commission, providing advice and strategic direction for various post grant matters. Although Christopher’s work spans a multitude of technologies, he has industry recognized capabilities in both antibodies and cell culture related technologies. Other technologies with which he has experience include molecular diagnostics, biosimilars/follow-on biologics, DNA/protein sequencing, recombinant DNA and genetic engineering, pharmaceutical formulations,